Andres Emanuelli Anzalotta, MD
Ophthalmology · Corozal, PRNPI 1023213154
Payments from drug & device makers
What this record shows
This record is dominated by consulting fees: $40,798 of the $49,844 with a category attached, or 81.9%. 20 manufacturers reported payments, led by Novartis at 29.3% of the total. 2025 is the largest year on record at $17,338, 3.0 times the $5,686 reported in 2019. Among ophthalmology clinicians in PR with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 105 payments — averaging $474.70 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Novartis$15K
- Genentech, Inc.$11K
- Ocular Therapeutix, Inc.$9K
- Regeneron$7K
- Genentech USA, Inc.$3K
- AbbVie$2K
- plus $3K from 14 others
Across 890 payments — averaging $13,026 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Novartis$6.8M
- Genentech, Inc.$2.8M
- Regeneron$1.7M
- Roche TCRC, Inc.$188K
- F. Hoffmann-la Roche AG$93K
- AbbVie$42K
- plus $24K from 2 others
What the payments were for
- Consulting fees$40,79882%
- Speaking & faculty fees$2,4005%
- Travel & lodging$1,9284%
- Food & beverage$4,6069%
- Education$930%
- Gifts$190%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Novartis | 17 | $14,626 |
| Genentech, Inc. | 8 | $10,604 |
| Ocular Therapeutix, Inc. | 8 | $8,500 |
| Regeneron | 15 | $7,184 |
| Genentech USA, Inc. | 15 | $3,346 |
| AbbVie(2 entities) | 10 | $2,468 |
| Roche TCRC, Inc. | 3 | $1,273 |
| Regeneron Healthcare Solutions, Inc. | 12 | $669 |
| Alcon Puerto Rico Inc | 2 | $199 |
| Bausch & Lomb Americas Inc. | 2 | $186 |
| Davol Inc. | 1 | $139 |
| Mallinckrodt Hospital Products Inc. | 2 | $135 |
| Astellas Pharma US Inc | 1 | $122 |
| Amgen | 2 | $121 |
| F. Hoffmann-la Roche AG | 1 | $112 |
| Alcon | 1 | $52 |
| Mallinckrodt Enterprises LLC | 2 | $49 |
| ANI Pharmaceuticals, Inc. | 1 | $22 |
| Carl Zeiss Meditec AG | 1 | $19 |
| Eyepoint US, Inc. | 1 | $17 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- BEOVU$11,200
- Lucentis$7,490
- SUSVIMO$3,930
- EYLEA HD$2,446
- OZURDEX$2,200
- Non-Covered Product$1,273
- EYLEA$1,092
- VABYSMO$1,003
- STELLARIS$141
- Phasix Mesh$139
- Unity$132
- Izervay$122
- BUPARLISIB$122
- PAVBLU$100
How this compares
$49,844 in reported general payments places this provider in the 95th percentile of 214 ophthalmology providers in Puerto Rico.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Fluorometholone | 384 | $25,891 |
| Prednisolone Acetate | 504 | $20,295 |
| Difluprednate | 146 | $20,159 |
| MounjaroTirzepatide | 12 | $15,216 |
| LumiganBimatoprost | 41 | $10,477 |
| Brimonidine Tartrate-TimololBrimonidine Tartrate/Timolol | 70 | $9,523 |
| Dorzolamide-TimololDorzolamide Hcl/Timolol Maleat | 258 | $8,561 |
| Ofloxacin | 246 | $5,396 |
| CombiganBrimonidine Tartrate/Timolol | 26 | $5,393 |
| Latanoprost | 407 | $4,887 |
| Brimonidine Tartrate | 295 | $3,538 |
| Ketorolac Tromethamine | 116 | $2,132 |
| Atropine Sulfate | 40 | $1,632 |
| Dorzolamide Hcl | 46 | $1,483 |
| Tobramycin-DexamethasoneTobramycin/Dexamethasone | 27 | $1,224 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AbbVieLumigan, Combigan | $2,468 | $15,87067 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 214 ophthalmology providers in Puerto Rico.
Other ophthalmology in Corozal
- Maria Berrocal FernandezSan Juan$547K
- Jose MontesSan Juan$396K
- Armando OliverRio Piedras$251K
- Cristobal Cruz-ColonPonce$44K
- Juan Nevarez MarreroSan Juan$19K
- Natalio Izquierdo EncarnacionSan Juan$16K
- Ian PiovanettiSan Juan$11K
- Antolin Alvarez PontSanturce$10K
- Jaime Bravo CastroSan Juan$8K
- Gabriel Benitez BajandasHumacao$7K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.